Spinal Muscular Atrophy: Update in Best Clinical Care and Genetic Therapies

New
ICNA
Updated
Session Type
Language
English
Cost
Free
Self Assessment Activity available

🗓️ Event Details

  • 📅 Date: September 10, 2025

  • Time: 6:00 PM CET

  • Duration: 90 Minutes

  • 🌐 Language: English

  • 💰 Cost: Free

  • 📝 Self-Assessment Activity: Not available

 oie 1164025MeYEXnWT

Title: Spinal Muscular Atrophy: Update in Best Clinical Care and Genetic Therapies
Speakers: Tawfeg Ben-Omran; Chahnez Charfi Triki; Ramesh Konanki; Juliana Gurgel; Ann Mathew
When: September 10, 2025
Time: 6:00 PM CET

Click Here to Register

About the Talk

Speaker: Tawfeg Ben-Omran
Title: Spinal Muscular Atrophy: Update in Best Clinical Care and Genetic Therapies
About Topic:
This talk provides a concise overview of the clinical and genetic aspects of SMA, along with updates on current genetic therapies and real-world treatment experiences. It emphasizes the critical importance of early diagnosis and intervention—best achieved through implementation of newborn screening programs.

Learning Objectives:
• Understand the genetic and clinical presentation of SMA
• Review management strategies using a multidisciplinary approach
• Explore novel therapies and therapeutic strategies in real-world practice

Speaker: Ann Mathew
Title: “Beyond drugs: multidisciplinary care that changes trajectories”

  • Respiratory protocols, nutrition, physio/OT, orthopaedics, scoliosis pathways.
  • Home-based care models, tele-rehab, caregiver training, assistive tech.
  • Outcome tracking that supports reimbursement and quality improvement.

Speaker: Ramesh Konanki
Title: “Closing the diagnostic gap: triage algorithms, confirmatory testing, and referral networks”

  • Sensible early-signs triage for primary care.
  • Affordable confirmatory testing options; lab turn-around targets.
  • Building state/regional hubs; leveraging government schemes & CSR.

Speaker: Juliana Gurgel
Proposed Title: “From pilot to policy: integrating SMA into newborn screening and national formularies”

  • Brazil pathway: pilot data → scale-up; payer negotiations; centre designation.
  • Managing therapy logistics (intrathecal vs oral vs vector-based) in a large federation.
  • Data for advocacy: outcomes, safety, and budget impact



Viewer Review

No viewer reviews
Already have an account? or Create an account

Add comment

Submit

Join Our Newsletter

Log in

X